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OBJECTIVE—CTLA4 gene variation associates with multiple
autoimmune disorders, including type 1 diabetes. The CTLA4
susceptibility allele was found to generate decreased levels of
mRNA encoding soluble CTLA-4 (sCTLA-4) relative to the full-
length isoform, the functional consequence of which is as yet
unknown. In this study, we investigated the contribution of
sCTLA-4 to immune regulation with the aim to elucidate the func-
tional basis of the disease association of CTLA4.
RESEARCH DESIGN AND METHODS—To model the disease-
associated splicing variation of CTLA4, we generated NOD mice
in which sCTLA-4 mRNA is silenced by RNA interference.
RESULTS—We found that loss of sCTLA-4 impairs the function
of regulatory T (Treg) cells. This functional defect could be
attributed, at least in part, to the failure of sCTLA-4 knockdown
(KD) Treg cells to downregulate dendritic cell costimulation.
sCTLA-4 KD Treg cells, in contrast with wild-type Treg cells,
failed to inhibit colitis induced by transfer of CD4
+CD45RBhi cells
into NOD.SCID animals. Furthermore, diminished sCTLA-4 ex-
pression accelerated the onset of autoimmune diabetes in trans-
genic mice.
CONCLUSIONS—Our results demonstrate that sCTLA-4 partic-
ipates in immune regulation by potentiating the function of Treg
cells. The functional outcome of silencing this splice variant in
the NOD model provides an explanation for the association of
CTLA4 variation with autoimmunity. Lower sCTLA-4 expression
from the susceptibility allele may directly affect the suppressive
capacity of Treg cells and thereby modulate disease risk. Our
unprecedented approach establishes the feasibility of modeling
splicing variations relevant to autoimmunity. Diabetes 60:1955–
1963, 2011
S
usceptibility to type 1 diabetes is modulated by
.40 genomic loci (1). Several likely causal genes,
including CTLA4, have been identiﬁed (1–4).
CTLA4 polymorphism associates with multiple
autoimmune disorders in addition to type 1 diabetes (4,5).
Yet the functional contribution to autoimmunity of the
disease-associated CTLA4 allele remains unknown. The
critical role of this gene in immune regulation is well
established and is best exempliﬁed by the phenotype of
Ctla4 knockout (KO) mice that succumb to severe lym-
phoproliferation within a few weeks of birth (6,7). Simi-
larly, the speciﬁc deletion of Ctla4 in Foxp3
+ regulatory
T (Treg) cells alone disrupts immune regulation and causes
lethal lymphoproliferation (8). CTLA-4 has been suggested
to fulﬁll its inhibitory function by several distinct mecha-
nisms. Its homology to the costimulatory molecule CD28
may allow CTLA-4 to sequester CD80 and CD86 that pro-
vide positive signals to T cells via CD28 (9). CTLA-4 has
also been shown to directly elicit negative signals that
counteract T-cell activation (10–13). In addition, CTLA-4
was found to prevent T lymphocytes from building lasting
interactions with antigen-presenting cells (APCs) (14). No-
tably, CTLA-4 was shown to act both in a cell-autonomous
and a non–cell-autonomous manner to modulate T-cell
responses (15).
Understanding the exact function of CTLA-4 has been
a long-standing challenge whose complexity further in-
creased with the discovery of alternative splice variants
(4,16,17). Ctla4 encodes a transcript with four exons.
Splicing generates a full-length transcript (ﬂCTLA-4) and
two shorter transcripts that skip exon 2 (ligand-binding
domain) or exon 3 (transmembrane domain). These shorter
mRNAs are translated into proteins termed “ligand-
independent” CTLA-4 (liCTLA-4, present in mouse but not
in human) (4,18) and “soluble” CTLA-4 (sCTLA-4, present in
both human and mouse) (4,16,17), respectively.
The diabetes-associated CTLA4 susceptibility allele has
been correlated to a decrease in sCTLA-4 mRNA relative
to the full-length transcript (4,19). Because the respective
function of these splice variants has not been resolved, the
consequence of a change in splicing frequency is unclear.
We decided to study the function of sCTLA-4 to understand
how decreased levels of this molecule might affect immune
regulation. Our aim was to determine whether a change in
sCTLA-4 levels could be causal for the disease association
of CTLA4 in humans. To this end, we chose to speciﬁcally
examine sCTLA-4 function within the context of the NOD
mouse model for type 1 diabetes (20). Ctla4 KO mice were
generated by deletion of exons 2 and 3, ablating expression
of all three isoforms (6,7). Because of overlapping exon
use between CTLA-4 splice variants, a conventional KO
approach cannot be used to delete either of the shorter
isoforms without also affecting ﬂCTLA-4. Instead, we ex-
ploited the posttranscriptional silencing mechanism of RNA
interference (RNAi) to target sCTLA-4 while retaining wild-
type (WT) levels of both ﬂCTLA-4 and liCTLA-4. We gen-
erated transgenic NOD mice in which only sCTLA-4 is
silenced by RNAi and found that loss of this splice variant
alone reduced the potency of Treg cells. Loss of sCTLA-4
accelerated type 1 diabetes onset, supporting a causal role
for the splicing variation associated with autoimmunity in
humans. Together, our results demonstrate a signiﬁcant role
for sCTLA-4 in immune regulation.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Mice.WT,transgenic,and congenicNODmicewerebredandmaintainedatthe
University of Würzburg in accordance with institutional guidelines. All
experiments were approved by the university animal care committee. Lenti-
viral transgenic mice were generated by microinjection of single-cell NOD
embryos as described previously (21).
Lentiviral construct for shRNA expression. The pLB vector (21) was
modiﬁed by replacing the U6-shRNA-CMV-GFP cassette with a CMV-GFP-
mir30shRNA cassette (from pPRIME, 22). pLB was digested with EcoRI, and
the overhangs were blunted before digesting the vector with XbaI. The
products of the digest were separated by gel electrophoresis, and the back-
bone was extracted from the gel and puriﬁed. The CMV-GFP-mir30shRNA
cassette was cut out from pPRIME by XbaI/PmeI double-digest, gel puriﬁed as
above, and ligated into the pLB backbone to generate the pLBM vector. shRNA
constructs were cloned into pLBM using the restriction sites XhoIa n dEcoRI
located in the mir30 cassette. Positive clones were identiﬁed by colony PCR
and veriﬁed by sequencing. Lentiviral particles were generated as described
previously (21), and high-titer preparations (.10
8 infectious particles/mL)
were used for NOD embryo injection.
Validation of shRNA potency by luciferase reporter assay. The cDNA for
ﬂCTLA-4, sCTLA-4, and liCTLA-4 (gift from Dr. Vijay Kuchroo, Harvard Medical
School) were cloned into the 39 UTR of the Renilla luciferase gene in the
psiCheck2 vector (Promega, Madison, WI). pLBMs containing a control shRNA
or shRNA sequences against the exon 2–exon 4 junction sequence of sCTLA-4
were cotransfected with the psiCheck2 reporter constructs into 293FT cells.
Cells were lysed 48 h after transfection, and luciferase activities were mea-
sured in a Fluostar Optima luminometer (BMG Labtech, Offenburg, Germany).
Renilla luciferase activity was normalized to Fireﬂy luciferase activity that is
also expressed from the psiCheck2 plasmid to adjust for transfection efﬁ-
ciency. Renilla luciferase activity of control shRNA transfected cells was used
as a baseline value (100% relative luminescence). Results from duplicate trans-
fections expressed in percent relative luminescence are shown. The most efﬁcient
and speciﬁc shRNA target sequence, used for transgenesis, was GCAGATTT-
ATGTCATTGCTAAA.
Quantitation of CTLA-4 mRNA levels ex vivo. WT and sCTLA-4 knockdown
(KD) mice were each injected with 5 mg anti-CD3 antibody intravenously. Six
hours later, the animals were killed and dissected, and the spleen was imme-
diately homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA). Extracted
RNA was reverse-transcribed, and mRNA levels for sCTLA-4, liCTLA-4, and
ﬂCTLA-4 were quantitated by Taqman PCR using the following forward primer,
reverse primer, and probe, respectively: sCTLA-4, acccaccgccatactttgtg/
aggacttcttttctttagcaatgacat/aatctgcgtcccgttgcccatg; liCTLA-4, gccttttgtagccctgctca/
tcagaatccgggcatggtt/ttcttttcatcccagtcttctctgaagatcca; and ﬂCTLA-4, actcatgta-
cccaccgccata/gggcatggttctggatcaat/catgggcaacgggacgcagatttat.
Flow cytometry. All ﬂow cytometry measurements were performed on
a FACSCanto II ﬂow cytometer (BD Biosciences, Bedford, MA), and data were
analyzed using FlowJo software (Tree Star Inc., Ashland, OR).
Cell puriﬁcation. Cell populations used in culture were magnetically isolated
using MACS beads (Miltenyi Biotec, Cologne, Germany) for negative selection
of CD4
+ cells and positive selection of CD25
+, CD62L
+, or CD11c
+ cells
according to the manufacturer’s instructions.
Proliferation assays. [
3H]thymidine (0.5 mCi/well) was added to cultures for
the last 16 h, and incorporation was measured by scintillation measurement
using a microbeta-counter (Perkin-Elmer, Foster City, CA). Results are
expressed in counts per minute.
Regulatory T-cell assays. T-cell subsets were puriﬁed from lymph nodes and
spleen by magnetic separation using a CD4
+CD25
+ isolation kit (Miltenyi
Biotech) according to the manufacturer’s instructions. CD4-depleted cells
from WT mice were irradiated (20 Gy) and used as APC (4 3 10
5/well).
CD4
+CD25
2 Teff cells (2.5 3 10
4/well) were mixed with CD4
+CD25
+ Treg cells
at the indicated ratios and stimulated with 1 mg/mL anti-CD3 antibody in
Roswell Park Memorial Institute-1640 medium supplemented with 10% fetal
bovine serum, penicillin/streptomycin, L-glutamine, 2-mercaptoethanol, so-
dium pyruvate, and HEPES (all from Gibco/Invitrogen, Carlsbad, CA).
Cytokine measurements. Cytokine concentrations in culture supernatants
were measured by ELISA (eBioscience, San Diego, CA) and Cytometric Bead
Array (BD Biosciences) according to the manufacturers’ instructions.
Dendritic cell coculture assay. Spleens were digested with Liberase
Blendzyme 2 (Roche, Mannheim, Germany), and splenic dendritic cells (DCs)
were puriﬁed by magnetic separation using anti-CD11c beads (Miltenyi Bio-
tech) according to the manufacturer’s instructions. DCs (4 3 10
4/well) were
cultured with CD4
+CD25
+ and CD4
+CD25
2 T cells (1.6 3 10
5/well), as in-
dicated, in the presence of 1 mg/mL anti-CD3 antibody. T cells were stained
with CFSE (Invitrogen) before culture, and DCs (CD11c
+CFSE
2) were ana-
lyzed for CD86 expression by ﬂow cytometry after 40 h of culture.
Colitis induction. WT CD4
+CD45RB
hi T cells (4 3 10
5) were injected alone
or with CD4
+CD25
+ T cells (10
5) from WT or sCTLA-4 KD NOD mice into
NOD.SCID recipients. Mice were killed after 8–9 weeks, and parafﬁn-embedded
colon sections were stained with hematoxylin–eosin and scored for disease in
a blind fashion on a scale from 0 to 4 (23): grade 0 = no changes; grade 1 =
minimal scattered mucosal inﬂammatory cell inﬁltrates, with or without min-
imal epithelial hyperplasia; grade 2 = mild scattered to diffuse inﬂammatory
cell inﬁltrates, sometimes extending into the submucosa and associated with
erosions, with minimal to mild epithelial hyperplasia and minimal to mild
mucin depletion from goblet cells; grade 3 = mild to moderate inﬂammatory
cell inﬁltrates that are sometimes transmural, often associated with ulceration,
with moderate epithelial hyperplasia and mucin depletion; grade 4 = marked
inﬂammatory cell inﬁltrates that are often transmural and associated with
ulceration, with marked epithelial hyperplasia and mucin depletion.
Statistical analyses. All statistical analyses were performed using the Prism
software package (GraphPad Software Inc., La Jolla, CA). Survival curves were
compared using the log-rank test. All other comparisons were performed by
unpaired t test.
RESULTS
Generation of sCTLA-4 KD NOD mice. To investigate
the role of sCTLA-4 in immune function and autoimmunity,
we set out to generate NOD mice lacking this splice vari-
ant. A KO approach is not suited to ablating a single
transcript composed of only exons that are also present in
other splice variants of the same gene. Because RNAi is
a posttranscriptional event, it is more amenable to target-
ing individual splice variants, and we therefore assessed
the feasibility of silencing sCTLA-4 in an isoform-speciﬁc
manner using short-hairpin RNA (shRNA) constructs. To
achieve speciﬁcity, we designed shRNA sequences that
span the exon 2–exon 4 junction unique to the transcript
encoding sCTLA-4 (Fig. 1A). Functional validation of sev-
eral sequences identiﬁed one shRNA construct capable of
targeting sCTLA-4 mRNA for degradation without affecting
either ﬂCTLA-4 or liCTLA-4 (Fig. 1B). Silencing was highly
speciﬁc for the sCTLA-4 variant despite a high degree of
sequence identity between the target region and ﬂCTLA-4
(86% identity, Supplementary Fig. 1). We used this construct
to generate transgenic NOD mice by perivitelline injection
of lentivirus into NOD zygotes (21). The founder line used
for all subsequent experiments was determined to contain
a single copy of the lentiviral transgene (Supplementary Fig.
2). Transgene expression was detected in 75% of cells on
average (Fig. 1C), and expression was stable within in-
dividual mice and throughout generations. Quantitative
PCR measurements conﬁrmed that sCTLA-4 mRNA was
signiﬁcantly reduced in splenocytes from transgenic mice
(Fig. 1D). In contrast, both ﬂCTLA-4 and liCTLA-4 levels
were comparable to those of control animals.
sCTLA-4 silencing diminishes the suppressive activity
of Treg cells in vitro. Initial characterization of lymphoid
organs from sCTLA-4 KD mice showed that T-cell de-
velopment was unaffected (Fig. 2A and B). Neither thymic
nor peripheral T-lymphocyte populations differed in phe-
notype or frequency between WT and sCTLA-4 KD mice.
T lymphocytes from sCTLA-4 KD mice also proliferated
similarly to their WT counterpart in response to in vitro
stimulation (Fig. 2C). Further characterization of CD4
+
subsets showed that Foxp3
+ Treg cells were normal in
both their frequency and their expression of Foxp3, CD25,
total CTLA-4, and GITR (Fig. 3).
Several recent reports have highlighted the role of
CTLA-4 in the function of Treg cells (8,23–25). Although
the assumption until now has been that ﬂCTLA-4 is the
major isoform contributing to overall CTLA-4 function, we
wanted to investigate whether sCTLA-4 participates in the
suppressive function of Treg cells. Treg cells from sCTLA-4
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a 1:1 ratio of effector T cells (Teff) to Treg cells. However,
at higher ratios, suppression by transgenic Treg cells was
weaker compared with that effected by WT cells. At ratios
of 5:1 (Teff:Treg) or higher, inhibition of Teff cell pro-
liferation and interferon-g production was signiﬁcantly
dampened when Treg cells from sCTLA-4 KD mice were
used (Fig. 4A and B). Similar results were observed when
Teff cells from sCTLA-4 KD mice were used (Supplemen-
tary Fig. 3). Loss of sCTLA-4 is apparently sufﬁcient to
impair the suppressive function of Treg cells. This partial
defect could have a developmental origin, or alternatively,
sCTLA-4 could directly contribute to the effector function
of Treg cells. To distinguish between these two possibili-
ties, we generated induced-Treg cells (iTreg) (26). The in
vitro differentiation of these cells can be assumed to by-
pass potential defects in thymic Treg cell development.
CD4
+CD62L
+ T cells were cultured in the presence of
transforming growth factor (TGF)-b, and their differentia-
tion into iTreg cells was assessed by intracellular Foxp3
measurement. Naïve T lymphocytes from WT and sCTLA-4
KD NOD mice could be differentiated into iTreg cells with
similar efﬁciencies, with ;80–85% of CD4
+ cells expressing
Foxp3 after TGF-b treatment (Fig. 4C). The suppressive
capacity of iTreg cells derived from sCTLA-4 KD mice was
again decreased at higher Teff:Treg ratios (Fig. 4D), directly
implicating sCTLA-4 in the effector mechanism of Treg cells.
Treg cell–derived sCTLA-4 modulates APC costimula-
tion. CTLA-4 is thought to perform its function, at least in
part, by binding to costimulatory molecules on the surface
of APCs (9–13). The exact mechanism by which such
binding translates into inhibition of T-cell activation is
unclear. One possibility pertinent to the function of Treg
cells is the direct downmodulation of these molecules on
the surface of APC (8,27). Wing et al. (8) have shown that
Ctla4-deﬁcient Treg cells fail to counter the upregulation
of costimulatory molecules on DCs in culture. However,
the respective contributions of ﬂCTLA-4 and sCTLA-4 to
this phenomenon have not been investigated. To test
whether sCTLA-4 participates in the modulation of APC
costimulation, we cultured DCs with Treg cells from ei-
ther WT or sCTLA-4 KD mice, in the presence or absence
of Teff cells. Consistent with previous reports (8,24,27),
the presence of Treg cells from WT mice diminished
CD86 expression on the DC surface. In contrast, sCTLA-
4 KD Treg cells were only partially capable of inhibiting
CD86 expression (Fig. 5), suggesting a role for Treg cell–
derived sCTLA-4 in modulating the costimulatory po-
tential of APCs.
Loss of sCTLA-4 impairs Treg cell activity in vivo.
Having established that the loss of sCTLA-4 affects the
suppressive activity of Treg cells in vitro, we wanted
to address whether the defects observed in vitro directly
affect immune regulation in vivo. CTLA-4 has been
shown to be critical to the function of Treg cells within
a colitis model where disease is induced by transfer of
CD4
+CD45RB
hi T cells and can be suppressed by the co-
transfer of CD4
+CD25
+ T cells (23,28). Although this colitis
model is not usually used in conjunction with the NOD
mouse strain, one earlier study reported colitis induction
FIG. 1. Generation of sCTLA-4 KD NOD mice. A: Schematic representation of the exon structure of the ﬂCTLA-4, liCTLA-4, and sCTLA-4 mRNAs.
The position of the shRNA target sequence is indicated. B: The potency and speciﬁcity of sCTLA-4 silencing were validated in a luciferase reporter
assay, where shRNA efﬁciency was tested individually on sCTLA-4, liCTLA-4, and ﬂCTLA-4 reporter constructs. Representative results of four
similar experiments are shown. C: sCTLA-4 KD mice were generated by lentiviral transduction of NOD embryos with a vector containing GFP, and
transgene expression was measured by ﬂow cytometry. Expression in CD4
+ and CD8
+ T cells from two representative WT and sCTLA-4 KD mice is
shown. The transgene was bred to homozygosity to improve expression. D: mRNA levels for all three CTLA-4 isoforms were measured in splenocyte
lysates prepared 6 h after intravenous anti-CD3 antibody injection (5 mg/mouse) to increase overall CTLA-4 expression. n = 3 mice for both groups,
P = 0.0353 for sCTLA-4, with a reduction of ;70% (1.74 cycles). Representative results of three similar experiments are shown.
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+CD45RB
hi NOD T cells into NOD.
SCID animals (29). We hypothesized that the defect in Treg
cell function caused by the loss of sCTLA-4 may be appar-
ent in this model, because overall CTLA-4 blockade had been
shown to impair the suppressive activity of CD4
+CD25
+ cells
i nt h es a m ec o n t e x t( 2 8 ) .T h et r a n s f e ro fC D 4
+CD45RB
hi cells
into NOD.SCID recipients resulted in mild but signiﬁcant
pathology (Fig. 6). The simultaneous transfer of WT Treg
cells markedly reduced colon inﬂammation. In contrast, the
cotransfer of sCTLA-4 KD Treg cells failed to inhibit patho-
genic CD4
+CD45RB
hi cells and resulted in pathology com-
parable to that observed in recipients of CD4
+CD45RB
hi cells
alone. These data implicate sCTLA-4 in Treg cell function in
vivo. Results from these experiments therefore support the
notion that sCTLA-4 expression modulates immune reactivity
by contributing to the suppressive function of Treg cells.
sCTLA-4 silencing accelerates diabetes onset. The
NOD mouse strain is the most widely used animal model
for type 1 diabetes (20). The rationale for targeting sCTLA-4
in the NOD model was to replicate the human disease-
associated CTLA4 polymorphism. We hypothesized that if
the splicing difference observed in humans is causal for
the diabetes association of this gene, sCTLA-4 silencing
would increase disease frequency in NOD mice. Because
most NOD female mice develop diabetes, we anticipated
that an increase in disease may not be discernible in the
fully susceptible background. We therefore also bred the
sCTLA-4 KD transgene onto the protected Idd5.1 congenic
background (30). We chose this particular congenic line
because the effect of the Idd5.1 locus is due to a protec-
tive allele of Ctla4 that generates higher liCTLA-4 levels
(30,31). The protection is independent of a change in
sCTLA-4 itself, yet allows the evaluation of sCTLA-4
function within the context of a protective Ctla4 allele. We
therefore sought to investigate whether the loss of sCTLA-4
could diminish the protective effect of this allele. We found
that sCTLA-4 silencing had no signiﬁcant effect in the fully
susceptible NOD background (Fig. 7A). Female sCTLA-4
KD NOD mice developed diabetes with a frequency and
onset kinetics comparable to those of the WT NOD cohort.
However, although the increase in disease frequency caused
by sCTLA-4 knockdown in Idd5.1 mice did not reach sig-
niﬁcance (Fig. 7A), gene silencing fully reverted the delay
in diabetes onset effected by the protective Idd5.1 allele
(Fig. 7B). These results provide the ﬁrst functional evidence
that loss of sCTLA-4 increases susceptibility to type 1
diabetes.
DISCUSSION
The most recent genome-wide association study of type 1
diabetes, combined in a meta-analysis with two previous
similar studies, reported no fewer than 41 distinct genomic
loci associated with disease (1). Among the likely causal
gene variants identiﬁed to date are several genes known to
play a pivotal role in immune regulation, such as IL2,
IL2RA, and CTLA4. Yet, each of these genes makes only
a modest contribution to disease risk (1,3). Most disease
gene variants are indeed characterized by seemingly mild
alterations in gene expression or function (4,32,33). For
example, although CTLA-4 function is known to be critical
in mice (6,7), the human diabetes-associated CTLA4 sus-
ceptibility allele differs from the protective allele only in its
splicing frequency (4,19). It is difﬁcult to ascribe causality
to such subtle variations, particularly when their func-
tional consequences are unknown. The respective function
FIG. 2. T-cell development is not affected by sCTLA-4 silencing. A:
Representative analysis of WT and sCTLA-4 KD thymocytes stained
with anti-CD4, anti-CD8, anti-CD25, and anti-Foxp3 antibody. Top:
Total thymocytes. Bottom: Gated on CD4
+CD8
2 (CD4SP) cells. B:
Representative analysis of WT and sCTLA-4 KD lymph node cells
stained with anti-TCRb, anti-CD4, and anti-CD8 antibody. Top:A l l
lymph node cells. Bottom: Gated on TCRb
+ cells. C: Lymph node cells
from WT and sCTLA-4 KD mice were stimulated with anti-CD3 anti-
body, and proliferation was measured after 72 h. Results are repre-
sentative of three similar experiments; error bars indicate SEM.
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solved to date. Consequently, it was unclear until now
whether the shift in CTLA4 splicing frequency is causal for
disease association and how this change in splicing may
functionally affect immune regulation.
Modeling subtle gene variations, and splicing variations
in particular, poses a signiﬁcant technical challenge that
cannot be approached with conventional methods. To over-
come this issue, we pioneered the use of isoform-speciﬁc
RNAi in the mouse. We generated transgenic NOD mice in
which a single splice variant of Ctla4, namely, sCTLA-4, is
silenced by RNAi, and were thereby able to model the
CTLA4 gene variation associated with type 1 diabetes in
humans. Our ﬁndings using this novel approach demon-
strate that loss of sCTLA-4 increases disease susceptibility
and suggest that the splicing change caused by the disease-
associated CTLA4 allele in humans may directly affect im-
mune regulation.
FIG. 3. Treg cell frequency and cell surface markers are not perturbed by loss of sCTLA-4. A: CD25 and Foxp3 expression in TCR
+CD4
+ lymph node
cells from WT and sCTLA-4 KD mice. B–E: Puriﬁed T-cell subpopulations were stimulated with irradiated splenocytes and anti-CD3 antibody, and
expression proﬁles were analyzed at the indicated times. CTLA-4 expression (intracellular staining) (B and C) and GITR expression (D and E)i n
CD4
+CD25
2 cells (B and D) and CD4
+CD25
+ cells (C and E) from WT (black line) and sCTLA-4 KD (ﬁlled histogram) mice are shown.
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in Treg cell function. Treg cells were shown to depend on
CTLA-4 ;10 years ago (28,34). Several more recent studies
have further highlighted the reliance of Treg cells on
CTLA-4 as an effector of immune regulation (8,23–25,35).
Read et al. (23,28) showed in a colitis model that CTLA-4
blockade was sufﬁcient to abrogate protection from dis-
ease by Treg cells. Notably, their work demonstrated that
CTLA-4 antibody acted directly on Treg cells, and that anti-
CTLA-4 Fab fragments were sufﬁcient to inhibit Treg cell
function (23). Similarly, You et al. (35) showed that CTLA-4
blockade accelerated disease in NOD mice and that this
effect was dependent on the presence of Treg cells. These
results are consistent with our ﬁndings that sCTLA-4 con-
tributes to Treg cell effector mechanisms, as shown by the
partial defect of iTreg cells derived from sCTLA-4 KD mice
and the reduced suppressive capacity of sCTLA-4 KD Treg
cells both in vitro and in vivo. Studies using both antibody
blockade and cells from Ctla4-deﬁcient mice showed that
CTLA-4 expressed by Treg cells is involved in the modu-
lation of APC costimulation (8,36). Our data using Treg
cells from sCTLA-4 KD mice suggest that this function may
be fulﬁlled in part by the soluble isoform of CTLA-4. Re-
cent work by Qureshi et al. (37) has demonstrated that
ﬂCTLA-4, owing to its capacity to bind and internalize
CD80 and CD86, can substantially deplete costimulatory
molecules from the APC surface. The relative contribu-
tions of the soluble and full-length CTLA-4 isoforms to the
mechanisms by which CTLA4 regulates T-cell responses
in a cell-extrinsic manner therefore remain to be clariﬁed.
Notably, the partial defect we observed when using sCTLA-4
KD Treg cells to inhibit Teff cell proliferation in vitro mir-
rors that described by Wing et al. (8) in the context of Treg
cells with a Foxp3-dependent Ctla4 deletion. In vivo data
from Wing et al. (8) support the notion that a complete loss
of Ctla4 in the Treg cell compartment has much more se-
vere consequences than the mere loss of sCTLA-4. Never-
theless, sCTLA-4 KD and Ctla4-deﬁcient Treg cells display
similarities, particularly in vitro, implying a signiﬁcant role
for sCTLA-4 in overall CTLA-4 function.
Because the loss of sCTLA-4 alone compromises im-
mune regulation, it is likely that its function is distinct from
and not redundant with that of ﬂCTLA-4. In the context of
autoimmune diabetes, the effect of sCTLA-4 silencing was
only detectable in combination with the protective Idd5.1
allele derived from the B10 background that generates
higher amounts of liCTLA-4 (18,31). The liCTLA-4 splice
variant has been proposed to regulate the activation
threshold of effector/memory T cells in a cell-autonomous
manner (18). We speculate that sCTLA-4, which likely acts
cell-extrinsically, only signiﬁcantly affects the diabetogenic
T-cell response when effector T cells are not already
sensitized by the NOD susceptibility allele at Idd5.1.T h e
hyperreactivity of effector T cells related to liCTLA-4
deﬁciency in the NOD background may overshadow the
partial defect in Treg cell function caused by sCTLA-4
silencing. Restoring liCTLA-4 levels with the protective
Idd5.1 allele in NOD Idd5.1 congenic mice may then in
turn reveal the functional consequence of sCTLA-4 silenc-
ing. Of note, the human CTLA4 gene does not generate
a ligand-independent splice variant (4). In the complete
absence of liCTLA-4, it is plausible that the function of
sCTLA-4 in humans may be more critical in the regulation of
T-cell responses than can be inferred from the mouse
model where liCTLA-4 also contributes to Ctla4-mediated
regulation.
FIG. 4. sCTLA-4 silencing diminishes the suppressive activity of Treg cells in vitro. A and B: WT CD4
+CD25
2 Teff cells and WT or sCTLA-4 KD
CD4
+CD25
+ Treg cells were stimulated with irradiated splenocytes and anti-CD3 antibody at the indicated cell ratios. Proliferation (A) or cytokine
production (B) was measured after 72 h. A: P = 0.0003 and P = 0.05 at the 2:1 and 5:1 ratios, respectively. B: P = 0.0243 for interferon-g at the 5:1
ratio. C and D: CD4
+CD62L
+ T cells from WT or sCTLA-4 KD mice were stimulated with anti-CD3 and anti-CD28 antibody in the presence or
absence of TGF-b (2 ng/mL) for 96 h, and Foxp3 expression was measured (C). Freshly isolated WT CD4
+CD25
2 Teff cells and TGF-b–treated cells
(iTreg) were then stimulated with irradiated splenocytes and anti-CD3 antibody at the indicated cell ratios (D), and proliferation was measured at
72 h. D: P = 0.0027 at the 10:1 ratio. All data are representative of three or more experiments. Error bars indicate SEM.
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function (8,15,23–25,37) have addressed the potential
contribution of the minor splice isoforms of CTLA-4. The
technical hurdles involved and the lack of adequate
reagents available are obvious deterrents to more detailed
functional analyses. But it is clear that further studies
are required to determine exactly which roles the in-
dividual CTLA-4 splice variants fulﬁll, particularly if we
FIG. 5. Treg cell–derived sCTLA-4 modulates APC costimulation. Splenic CD11c
+ DCs from WT mice were cultured alone (ﬁlled histogram), with
WT CD4
+CD25
+ Treg cells (gray line), or with sCTLA-4 KD CD4
+CD25
+ Treg cells (black line) in the presence or absence of WT CD4
+CD25
2 Teff
cells. CD86 expression was measured on CD11c
+ cells after 40 h. A: Representative ﬂow cytometry histograms. B: CD86 expression on DCs
cocultured with Treg cells relative to that of DCs cultured alone (combined results from two experiments are shown). P = 0.0494 and P = 0.041 for
DCs with Treg cells only and Treg cells with Teff cells, respectively.
FIG. 6. Loss of sCTLA-4 impairs Treg cell activity in vivo. NOD.SCID mice were injected with CD4
+CD45RB
hi T cells from WT NOD animals, with or
without CD4
+CD25
+ Treg cells from WT or sCTLA-4 KD mice. A: Individual colitis scores (averaged from four histologic sections per mouse) from
two independent experiments (n =1 7 –21 per group). CD45RB
hi vs. CD45RB
hi+wt Treg P = 0.045. CD45RB
hi+wt Treg vs. CD45RB
hi+sCTLA-4 KD
Treg: P = 0.0116. CD45RB
hi vs. CD45RB
hi+sCTLA-4 KD Treg: P = 0.83. *Signiﬁcant P values (P < 0.05). B: Representative histology for colon
sections from all four groups. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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at both a cell-intrinsic and a cell-extrinsic level (15).
In conclusion, we have investigated the function of the
soluble splice variant of CTLA-4 with the aim to explain
the association of CTLA4 variation with autoimmunity in
humans. We found that loss of sCTLA-4 impairs the func-
tion of Treg cells and compromises immune regulation,
with the notable consequence of increasing the risk of
autoimmunity in the NOD background. Our study provides
the ﬁrst evidence for a causal relationship between the
autoimmunity-associated splicing variation of CTLA4 and
the disease risk. Last, our work underscores the utility of
RNAi to study the function of single splice variants in vivo.
Work by Wang et al. (38) revealed that .90% of human
genes are subject to alternative splicing. In light of this
report and the likely contribution of alternative splicing to
phenotypic variability, the novel approach we have de-
scribed will prove useful for future studies aiming to in-
vestigate disease-associated gene variants.
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